Andrographolide induces apoptosis in human osteosarcoma cells via the ROS/JNK pathway

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Osteosarcoma is the most prevalent primary bone cancer with poor long-term patient survival.
• Andrographolide, a component of traditional Chinese medicine, demonstrates anticancer properties in various cancer types.
• The specific mechanisms of andrographolide's action on osteosarcoma remain largely uncharacterized.

Purpose of the Study:

• To investigate the efficacy of andrographolide against osteosarcoma.
• To elucidate the underlying molecular mechanisms of andrographolide's antitumor effects in osteosarcoma cells.
• To evaluate andrographolide's therapeutic potential for osteosarcoma treatment.

Main Methods:

• In vitro studies using osteosarcoma cell lines to assess proliferation, cell cycle, and apoptosis.
• Analysis of reactive oxygen species (ROS) production and JNK signaling pathway activation.
• In vivo experiments in animal models to evaluate tumor growth inhibition.
• Pharmacological inhibition of JNK and scavenging of ROS to determine pathway involvement.

Main Results:

• Andrographolide significantly inhibited osteosarcoma cell proliferation by inducing G2/M cell cycle arrest.
• Treatment with andrographolide promoted caspase-mediated apoptosis in osteosarcoma cells.
• Andrographolide-induced apoptosis and cell cycle arrest were mediated by the ROS/JNK signaling pathway.
• In vivo studies confirmed that andrographolide suppressed tumor growth by increasing ROS and activating JNK.

Conclusions:

• Andrographolide demonstrates significant antitumor activity against osteosarcoma.
• The mechanism involves ROS generation, JNK activation, G2/M cell cycle arrest, and apoptosis induction.
• Andrographolide presents a promising therapeutic candidate for osteosarcoma treatment.